Thread by @NadiaJamilMD

Kicking off Day 1 of @TheAACE Cardiometabolic Conference with "AACE Guideline Update: Developing a Diabetes Mellitus Comprehensive Care Plan" by Lawrence Blonde, MD (Ochsner Medical Center), moderated by S. Sethu K. Reddy, MD (CMU College of Medicine) #WeAreAACE #EndoTwitter

@TheAACE Grade B rec: Artificial intelligence systems, authorized by the FDA for detecting greater than mild diabetic retinopathy, can be used as an alternative to traditional screening approaches...facilitate diagnosis of vision-threatening retinopathy #AACE #Diabetes

Grade A: In T2DM and established ASCVD (or high risk) use GLP-1 RAs with proven CV benefits to reduce the risk of myocardial infarction, stroke, or CV death regardless of other glucose-lowering or cardiovascular therapies and independent of A1C #AACE #AACECVMET

Grade A: T2DM & est ASCVD (or very high risk), use SGLT2i's w/ proven CV benefits to reduce risk of hospitalization for heart failure (HF), major adverse cardiovascular events (MACE), or CV death regardless of background glucose-lowering therapy, CV therapy, or A1C. #AACECVMET

Grade C 15.6 Although inpatient CGM has not received regulatory approval, CGM may be useful in inpatient settings, while complying with institutional policies & safety precautions... may improve detection of severe hypoglycemic & hyperglycemic events #AACECVMET

Grade B 19.3 All men with CMD incl. prediabetes, metabolic syndrome, obesity, & T2D should be assessed for hypogonadism by history & physical exam; test for testosterone deficiency in persons with loss of libido &/or loss of muscle strength/mass, ED, osteopenia, or infertility

Rec 23 Grade B: Clinicians should assess social determinants of health (SDOH) in persons w/ DM to better guide them to the most appropriate resources. Interventional trials addressing SDOH & health inequities in DM are needed to evaluate reversibility of
their impact #AACECVMET

Great talk by Dr. Blonde! Key point: New antihyperglycemic agents with low risk for hypoglycemia & greater glucose-lowering efficacy, & at least 2 classes, SGLT2is and GLP-1 RAs, have been found to reduce the risk of CVD, HF, &/or CKD, independent of glycemic control. #AACECVMET